BIND Biosciences is a biopharmaceutical company focused on developing “smart” therapeutic targeted nanoparticles capable of differential delivery and controlled drug release to diseased tissue. The company’s technology enables highly selective targeting at the cellular level and is capable of delivering bioactive agents ranging from approved drugs to emerging drug modalities. The company’s product platform is broadly applicable across the therapeutic areas of oncology, inflammatory disease, cardiovascular disease and infectious disease. Their initial product development efforts are focused on cancer and cardiovascular disease with their first product anticipated to enter the clinic in 2009.